Ancora Advisors LLC Takes $1.39 Million Position in Bristol Myers Squibb Company $BMY

Key Points

• Ancora Advisors purchased 24,068 Bristol Myers Squibb shares worth approximately $1.39 million in the second quarter, while institutional investors collectively own 76.41% of the stock.
• BMY’s growth outlook received support from FDA approval of Zenbexus for relapsed or refractory multiple myeloma and continued development of deucravacitinib, though patent pressures and the end of its Cellares manufacturing partnership pose risks.
• The company exceeded quarterly earnings and revenue estimates, with analysts maintaining a consensus “Moderate Buy” rating and an average price target of $66.06; BMY also offers a $2.52 annual dividend, yielding about 3.8%.

Ancora Advisors LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 24,068 shares of the biopharmaceutical company's stock, valued at approximately $1,387,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Primecap Management Co. CA bought a new position in Bristol Myers Squibb during the 2nd quarter valued at $1,436,115,000. Canada Pension Plan Investment Board purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $241,223,000. Legal & General Group Plc bought a new position in shares of Bristol Myers Squibb during the second quarter valued at about $980,862,000. The Manufacturers Life Insurance Company purchased a new position in Bristol Myers Squibb during the second quarter worth about $125,419,000. Finally, Van Hulzen Asset Management LLC bought a new stake in Bristol Myers Squibb in the 2nd quarter worth about $975,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA approved Zenbexus (iberdomide), BMY’s first-in-class CELMoD therapy, for adults with relapsed or refractory multiple myeloma in combination with Darzalex and dexamethasone. The approval adds a potential oncology growth driver and expands BMY’s treatment portfolio in a major cancer market. New FDA Approval Gives Bristol-Myers Squibb Another Potential Oncology Growth Catalyst
• Positive Sentiment: Zenbexus received accelerated approval based on improved minimal residual disease-negative complete response rates. As the first approved CELMoD therapy in this setting, it could strengthen BMY’s competitive position in multiple myeloma, although continued approval depends on confirmatory evidence. Zenbexus First-in-Class CELMoD Approval
• Positive Sentiment: BMY is extending clinical development of deucravacitinib, signaling longer-term ambitions in autoimmune diseases and potentially broadening its growth pipeline beyond oncology. Bristol Myers Squibb Extends Deucravacitinib Program
• Neutral Sentiment: Camzyos continues to gain momentum, but its ability to offset patent pressures on older products depends partly on an upcoming FDA decision regarding adolescent use and competition from rival heart drugs. Can Camzyos Growth Offset Bristol Myers Patent Pressures?
• Negative Sentiment: BMY ended its Cellares partnership after concluding that the Cell Shuttle platform could not support commercial-scale manufacturing of Breyanzi. The decision raises questions about manufacturing capacity and the pace of Breyanzi growth, despite avoiding further spending under the agreement valued at up to $380 million. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth
• Negative Sentiment: Senior Vice President Phil Holzer sold 500 BMY shares for approximately $33,750, reducing his holdings by 2.88%. The small transaction is generally a limited signal, but may add modest caution after the stock’s recent advance. Bristol Myers Squibb SVP Sells 500 Shares
• Negative Sentiment: A patent dispute involving Cytokinetics creates additional legal uncertainty around BMY’s products and could increase future litigation or commercial risks. What Does Bristol Myers Squibb Face After Zenbexus Approval and Patent Action?

Wall Street Analysts Forecast Growth

Several research firms have commented on BMY. Jefferies Financial Group lowered shares of Bristol Myers Squibb from a "buy" rating to a "hold" rating in a research note on Wednesday, August 5th. Bank of America reduced their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a "buy" rating for the company in a report on Friday, July 10th. BMO Capital Markets reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. UBS Group lowered Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a report on Wednesday, August 5th. Finally, TD Cowen started coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a "buy" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of "Moderate Buy" and an average target price of $66.06.

Insider Activity

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the firm's stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.05% of the company's stock.

Bristol Myers Squibb Trading Down 0.9%

Shares of BMY opened at $66.93 on Friday. The business's 50-day moving average price is $61.51 and its 200-day moving average price is $59.64. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64. The stock has a market cap of $136.73 billion, a PE ratio of 14.74, a P/E/G ratio of 0.18 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. Bristol Myers Squibb's revenue was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. Bristol Myers Squibb's dividend payout ratio is presently 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source